[{"orgOrder":0,"company":"Universite de Sherbrooke Department of Medicine","sponsor":"Aker BioMarine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"||DGAT","graph1":"Neurology","graph2":"Preclinical","graph3":"Universite de Sherbrooke Department of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universite de Sherbrooke Department of Medicine \/ Aker BioMarine","highestDevelopmentStatusID":"4","companyTruncated":"Universite de Sherbrooke Department of Medicine \/ Aker BioMarine"},{"orgOrder":0,"company":"North-West University, South Africa","sponsor":"Swiss Federal Institute of Technology | MRC South Africa | Unilever","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SOUTH AFRICA","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Hematology","graph2":"Undisclosed","graph3":"North-West University, South Africa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"North-West University, South Africa \/ Swiss Federal Institute of Technology | MRC South Africa | Unilever","highestDevelopmentStatusID":"1","companyTruncated":"North-West University, South Africa \/ Swiss Federal Institute of Technology | MRC South Africa | Unilever"},{"orgOrder":0,"company":"Universidad de Granada","sponsor":"Puleva Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Universidad de Granada","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad de Granada \/ Puleva Biotech","highestDevelopmentStatusID":"9","companyTruncated":"Universidad de Granada \/ Puleva Biotech"},{"orgOrder":0,"company":"University of Leeds","sponsor":"The Leeds Teaching Hospitals NHS Trust | AdWare Research Ltd. | University of Bologna | European Union","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Leeds","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Leeds \/ The Leeds Teaching Hospitals NHS Trust | AdWare Research Ltd. | University of Bologna | European Union","highestDevelopmentStatusID":"1","companyTruncated":"University of Leeds \/ The Leeds Teaching Hospitals NHS Trust | AdWare Research Ltd. | University of Bologna | European Union"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Syneos Health","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Syneos Health"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Mead Johnson Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Mead Johnson Nutrition","highestDevelopmentStatusID":"1","companyTruncated":"University of Alabama at Birmingham \/ Mead Johnson Nutrition"},{"orgOrder":0,"company":"Mead Johnson Nutrition","sponsor":"International Peace Maternity and Child Health Hospital | Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Mead Johnson Nutrition","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mead Johnson Nutrition \/ International Peace Maternity and Child Health Hospital | Chinese Academy of Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Mead Johnson Nutrition \/ International Peace Maternity and Child Health Hospital | Chinese Academy of Sciences"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Pentec Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Dietary Supplement","year":"2023","type":"Agreement","leadProduct":"DHA","moa":"DHA level","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lobe Sciences \/ Pentec Health","highestDevelopmentStatusID":"15","companyTruncated":"Lobe Sciences \/ Pentec Health"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Hofseth BioCare","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Partnership","leadProduct":"DHA","moa":"||DHA level","graph1":"Immunology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Catalent Pharma Solutions \/ Hofseth BioCare","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ Hofseth BioCare"},{"orgOrder":0,"company":"Retrotope","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Retrotope \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Retrotope \/ Undisclosed"},{"orgOrder":0,"company":"Carol Fabian","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Neurology","graph2":"Phase I","graph3":"Carol Fabian","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Carol Fabian \/ Royal DSM","highestDevelopmentStatusID":"6","companyTruncated":"Carol Fabian \/ Royal DSM"},{"orgOrder":0,"company":"Danone","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Iron","moa":"||Hemoglobin (HB)","graph1":"Hematology","graph2":"Approved FDF","graph3":"Danone","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Danone \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Danone \/ Undisclosed"},{"orgOrder":0,"company":"Shandong Sibote Biotechnology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Neurology","graph2":"Undisclosed","graph3":"Shandong Sibote Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong Sibote Biotechnology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shandong Sibote Biotechnology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"IRCCS Eugenio Medea","sponsor":"DMF srl (Dietetic Metabolic Food)","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"IRCCS Eugenio Medea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRCCS Eugenio Medea \/ DMF srl (Dietetic Metabolic Food)","highestDevelopmentStatusID":"10","companyTruncated":"IRCCS Eugenio Medea \/ DMF srl (Dietetic Metabolic Food)"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Royal DSM","highestDevelopmentStatusID":"8","companyTruncated":"University of Oxford \/ Royal DSM"},{"orgOrder":0,"company":"Micelle BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Micelle BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Micelle BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Micelle BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Toronto","sponsor":"Unity Health Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"University of Toronto","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Toronto \/ Unity Health Toronto","highestDevelopmentStatusID":"6","companyTruncated":"University of Toronto \/ Unity Health Toronto"},{"orgOrder":0,"company":"Walter Reed National Military Medical Center","sponsor":"National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Immunology","graph2":"Undisclosed","graph3":"Walter Reed National Military Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walter Reed National Military Medical Center \/ National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"1","companyTruncated":"Walter Reed National Military Medical Center \/ National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oil","sponsorNew":"University of Cincinnati \/ Royal DSM","highestDevelopmentStatusID":"10","companyTruncated":"University of Cincinnati \/ Royal DSM"},{"orgOrder":0,"company":"Sarah Keim","sponsor":"Allen Foundation Inc. | March of Dimes | Cures Within Reach | Health Resources and Services Administration","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Sarah Keim","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarah Keim \/ Allen Foundation Inc. | March of Dimes | Cures Within Reach | Health Resources and Services Administration","highestDevelopmentStatusID":"11","companyTruncated":"Sarah Keim \/ Allen Foundation Inc. | March of Dimes | Cures Within Reach | Health Resources and Services Administration"}]
Find Clinical Drug Pipeline Developments & Deals for Docosahexaenoic Acid
Details :
Docosahexaenoic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognition Disorders.
Details :
Docosahexaenoic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
DHA is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Infant Nutrition Disorders.
Details :
Pentec will receive the exclusive rights to distribute Altemia (docosahexaenoic acid ethyl ester), a proprietary oral formulation of emulsified docohexanoic acid, clinically evaluated to restore DHA levels and help reduce inflammation associated with SCD...
Details :
Aptamil (Iron) First Infant Milk Stage 1(This infant formula is appropriate for most infants and meets U.S. nutrient requirements, but it may not be suitable for infants born prematurely, or with a low birth weight.
Details :
The partnership will see Catalent use its proprietary OptiGel® DR technology to encapsulate OmeGo (docosahexaenoic acid), HBC’s unique fish oil derived from sustainable, traceable, and fresh Norwegian Atlantic salmon.
Details :
Université de Sherbrooke in Canada will test if LYSOVETA, Aker BioMarine’s new delivery platform based on LPC-bound EPA/DHA from krill, is more effective in increasing the concentration of DHA in the brain and improving cognition.
Details :
Comapny's first D-PUFA drug candidate in development, RT001, has shown robust safety in over 50 patient years of oral dosing, and we expect RT011 to have a similar safety profile.
Details :
Docosahexaenoic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Inflammation.
Reset All
